Advertisement
Advertisement
AGEN
Agenus Inc.
6.83
USDSponsored
-0.17
-2.43%
Aug 11, 16:00 UTC -4
Closed
After-Market
6.87
+0.04
+0.59%
AGEN Earnings Reports
Positive Surprise Ratio
AGEN beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$34.88M
/$0.05
Implied change from Q2 26 (Revenue/ EPS)
+1.11%
/-600.00%
Implied change from Q3 25 (Revenue/ EPS)
+15.38%
/-97.42%
Agenus Inc. earnings per share and revenue
On Aug 06, 2026, AGEN reported earnings of -0.01 USD per share (EPS) for Q2 26, missing the estimate of 0.05 USD, resulting in a -119.61% surprise. Revenue reached 34.50 million, compared to an expected 34.68 million, with a -0.52% difference. The market reacted with a -3.73% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 34.88 million USD, implying an decrease of -600.00% EPS, and increase of 1.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Seer, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.31
Surprise
-12.56%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
FAQ
What were Agenus Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Agenus Inc. reported EPS of -$0.01, missing estimates by -119.61%, and revenue of $34.50M, -0.52% below expectations.
How did the market react to Agenus Inc.'s Q2 2026 earnings?
The stock price moved down -3.73%, changed from $7.78 before the earnings release to $7.49 the day after.
When is Agenus Inc. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Agenus Inc.'s next earnings report?
Based on 3
analysts, Agenus Inc. is expected to report EPS of $0.05 and revenue of $34.88M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement